231 related articles for article (PubMed ID: 17499730)
1. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
McLendon RE; Akabani G; Friedman HS; Reardon DA; Cleveland L; Cokgor I; Herndon JE; Wikstrand C; Boulton ST; Friedman AH; Bigner DD; Zalutsky MR
Nucl Med Biol; 2007 May; 34(4):405-13. PubMed ID: 17499730
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
Akabani G; Reardon DA; Coleman RE; Wong TZ; Metzler SD; Bowsher JE; Barboriak DP; Provenzale JM; Greer KL; DeLong D; Friedman HS; Friedman AH; Zhao XG; Pegram CN; McLendon RE; Bigner DD; Zalutsky MR
J Nucl Med; 2005 Jun; 46(6):1042-51. PubMed ID: 15937318
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.
Akabani G; Cokgor I; Coleman RE; González Trotter D; Wong TZ; Friedman HS; Friedman AH; Garcia-Turner A; Herndon JE; DeLong D; McLendon RE; Zhao XG; Pegram CN; Provenzale JM; Bigner DD; Zalutsky MR
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):947-58. PubMed ID: 10705017
[TBL] [Abstract][Full Text] [Related]
4. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120
[TBL] [Abstract][Full Text] [Related]
5. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
Reardon DA; Quinn JA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Dowell JM; Rich JN; Vredenburgh JJ; Desjardins A; Sampson JH; Gururangan S; Wong TZ; Badruddoja MA; Zhao XG; Bigner DD; Zalutsky MR
J Nucl Med; 2006 Jun; 47(6):912-8. PubMed ID: 16741299
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
Cokgor I; Akabani G; Kuan CT; Friedman HS; Friedman AH; Coleman RE; McLendon RE; Bigner SH; Zhao XG; Garcia-Turner AM; Pegram CN; Wikstrand CJ; Shafman TD; Herndon JE; Provenzale JM; Zalutsky MR; Bigner DD
J Clin Oncol; 2000 Nov; 18(22):3862-72. PubMed ID: 11078500
[TBL] [Abstract][Full Text] [Related]
7. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Reardon DA; Zalutsky MR; Akabani G; Coleman RE; Friedman AH; Herndon JE; McLendon RE; Pegram CN; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Guruangan S; Boulton S; Raynor RH; Dowell JM; Wong TZ; Zhao XG; Friedman HS; Bigner DD
Neuro Oncol; 2008 Apr; 10(2):182-9. PubMed ID: 18287339
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; Cokgor I; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Regalado LV; Sampson JH; Shafman TD; Wikstrand CJ; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2002 Mar; 20(5):1389-97. PubMed ID: 11870184
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
[TBL] [Abstract][Full Text] [Related]
10. [Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV)].
Pöpperl G; Götz C; Gildehaus FJ; Yousry TA; Reulen HJ; Hahn K; Tatsch K
Nuklearmedizin; 2002 Jun; 41(3):120-8. PubMed ID: 12109031
[TBL] [Abstract][Full Text] [Related]
11. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
Bigner DD; Brown MT; Friedman AH; Coleman RE; Akabani G; Friedman HS; Thorstad WL; McLendon RE; Bigner SH; Zhao XG; Pegram CN; Wikstrand CJ; Herndon JE; Vick NA; Paleologos N; Cokgor I; Provenzale JM; Zalutsky MR
J Clin Oncol; 1998 Jun; 16(6):2202-12. PubMed ID: 9626222
[TBL] [Abstract][Full Text] [Related]
12. Direct injection of 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose.
Hopkins K; Chandler C; Eatough J; Moss T; Kemshead JT
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):835-44. PubMed ID: 9531368
[TBL] [Abstract][Full Text] [Related]
13. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
Akabani G; Reist CJ; Cokgor I; Friedman AH; Friedman HS; Coleman RE; Zhao XG; Bigner DD; Zalutsky MR
J Nucl Med; 1999 Apr; 40(4):631-8. PubMed ID: 10210222
[TBL] [Abstract][Full Text] [Related]
14. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors.
Riva P; Arista A; Franceschi G; Frattarelli M; Sturiale C; Riva N; Casi M; Rossitti R
Cancer Res; 1995 Dec; 55(23 Suppl):5952s-5956s. PubMed ID: 7493376
[TBL] [Abstract][Full Text] [Related]
15. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
Lee Y; Bullard DE; Humphrey PA; Colapinto EV; Friedman HS; Zalutsky MR; Coleman RE; Bigner DD
Cancer Res; 1988 May; 48(10):2904-10. PubMed ID: 2452014
[TBL] [Abstract][Full Text] [Related]
16. An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial.
Tatter SB; Shaw EG; Rosenblum ML; Karvelis KC; Kleinberg L; Weingart J; Olson JJ; Crocker IR; Brem S; Pearlman JL; Fisher JD; Carson K; Grossman SA;
J Neurosurg; 2003 Aug; 99(2):297-303. PubMed ID: 12924704
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
Zalutsky MR; Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Wong TZ; Bigner DD
J Nucl Med; 2008 Jan; 49(1):30-8. PubMed ID: 18077533
[TBL] [Abstract][Full Text] [Related]
18. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome.
Devaux BC; O'Fallon JR; Kelly PJ
J Neurosurg; 1993 May; 78(5):767-75. PubMed ID: 8468607
[TBL] [Abstract][Full Text] [Related]
19. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.
Mamelak AN; Rosenfeld S; Bucholz R; Raubitschek A; Nabors LB; Fiveash JB; Shen S; Khazaeli MB; Colcher D; Liu A; Osman M; Guthrie B; Schade-Bijur S; Hablitz DM; Alvarez VL; Gonda MA
J Clin Oncol; 2006 Aug; 24(22):3644-50. PubMed ID: 16877732
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
Brown MT; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Reiman R; Felsberg GJ; Tien RD; Bigner SH; Zalutsky MR; Zhao XG; Wikstrand CJ; Pegram CN; Herndon JE; Vick NA; Paleologos N; Fredericks RK; Schold SC; Bigner DD
Clin Cancer Res; 1996 Jun; 2(6):963-72. PubMed ID: 9816257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
